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The effect of dopamine receptor blockade on natriuresis is 
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The effect of dopamine receptor blockade on natriuresis is dependent on 
the degree of hypervolemia. A number of different physiological factors 
and systems have been suggested to be responsible for the natriuretic 
effect following acute isotonic volume expansion (VE). The variation in 
suggestions may depend on the prevailing status of the systems gov-
erning fluid and electrolyte balance before VE, on the expansion 
medium and on the rate and degree of VE. A study was performed to 
determine whether the previously documented attenuating effect of 
dopamine receptor blockade on natriuresis induced by VE is dependent 
on the degree of hypervolemia. Anesthetized rats were pretreated with 
the dopamine receptor blockers haloperidol (l mg . kg-I body weight, 
i.p.), SCH 23390 (30 f,Lg . hr- I . kg-I i.v.) or vehicle and then SUbjected 
to VE at 2, 5 or 10% of body weight per hour. VE at 2, 5 and 10% 
increased sodium excretion in vehicle-pretreated animals 6-, 29- and 
130-fold, respectively. In the haloperidol-pretreated animals the natri-
uretic response (accumulated sodium excretion) to VE was attenuated 
by 67% (P < 0.05), 46% (P < 0.05) and 22% (NS) at the three degrees 
of expansion, respectively. The corresponding attenuation in SCH 
23390-treated animals were 60% (P < 0.05), 56% (P < 0.05) and 19% 
(NS), respectively. The gradual decrease in attenuation indicates that at 
varying degrees of hypervolemia, different physiological systems con-
tribute differently to the renal natriuretic response. The dopamine 
system seems to be relatively more important in promoting natriuresis 
at the lower (physiological) range of hypervolemia whereas in the high 
range other factors have a greater impact. 
Acute isotonic volume expansion (V E) is widely performed 
for evaluating the renal mechanisms of natriuresis. A number of 
different physiological factors and systems have been claimed 
to be involved in the natriuretic response to VE, such as renal 
hemodynamics [1], sympathetic nerves [2], physical factors [3], 
the atrial natriuretic factor (ANF) [4], the putative natriuretic 
hormone [5], prostaglandins [6] and dopamine [2, 7]. Reports 
vary as to which of these systems are considered major and 
minor contributors to the response. This variation may depend 
on the prevailing status of the systems governing fluid and 
electrolyte balance in the animals before the expansion proce-
dure, on the rate and degree of expansion and on the expansion 
medium used (such as, saline, blood or plasma). In previous 
investigations [8, 9] we found that the dopamine receptor 
blocker haloperidol attenuated the natriuretic response by 
about 50% in rats when they were subjected to VE correspond-
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ing to 2% of the body weight per hour. This would indicate that 
the dopamine system plays an important role in the natriuretic 
response to moderate VE. To test whether this attenuating 
effect on natriuresis varies with the degree of hypervolemia, we 
performed VE at three different levels with and without admin-
istration of the dopamine receptor blockers haloperidol and 
SCH 23390, and monitored the natriuretic response. 
Methods 
The experiments were performed on 66 male Sprague-Daw-
ley rats (Mollegaard, Copenhagen, Denmark) weighing 250 to 
320 g (282 ± 4 g, mean ± SEM). Prior to the experiment, all 
animals had free access to tap water and standardized chow 
(R3, Ewos, Sodertalje, Sweden) containing 3 g . kg-I sodium, 7 
g. kg-I potassium and 21% protein. The animals were anes-
thetized with an intraperitoneal injection of InactinR (120 
mg . kg-I body wt, Byk Gulden, Konstanz, FRG) and placed 
on a servo-controlled heating pad to maintain the rectal tem-
perature at 37.soC. 
Surgical preparation 
All animals were tracheostomized and polyethylene catheters 
were inserted into the right femoral vein and artery, the former 
for infusion of a Ringer solution ( in mM: 120 NaCi, 25 
NaHC03 , 2.5 KCI, 0.75 CaClz) or isotonic saline (0.9% NaCI), 
and the latter for continuous recording of blood pressure and 
blood sampling. The bladder was catheterized for sampling of 
urine. The animals were divided into nine groups: animals 
pretreated with vehicle (VE2, N = 8), haloperidol (H-VE2, N = 
8) or SCH 23390 (S-VE2, N = 5) and subjected to volume 
expansion at 2% of the body weight per hour, animals pre-
treated with vehicle (VE5, N = 9), haloperidol (H-VE5, N = 8) 
or SCH 23390 (S-VE5, N = 6) and subjected to 5% volume 
expansion, and animals pretreated with vehicle (VEto, N = 8), 
haloperidol (H-VEto, N = 8) or SCH 23390 (S-VElO, N = 6) 
and SUbjected to 10% volume expansion. 
Protocol 
After completion of the surgical procedures, all animals 
received the Ringer solution i.v. at 5.0 ml . hr- I . kg-I body 
weight. After 15 minutes of recovery, they were given an 
intraperitoneal injection of haloperidol (1 mg· kg-I body wt, 
injection volume 0.5 ml), an i.v. infusion of SCH 23390 (30 
j.Lg. kg-I bolus followed by 30 j.Lg . hr-I . kg-I) or vehicle and 
were then allowed to recover for 45 minutes. Thereafter three 
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consecutive urine sampling periods lasting 15 minutes each 
were started (control periods 1 to 3). When these periods were 
completed, the Ringers solution was replaced by saline and the 
rate of infusion was changed to either 20, 50 or 100 
ml . hr- t . kg- t body weight. At the same time three consecu-
tive IS-minute sampling periods were started (expansion peri-
ods 1 to 3). At the end of the study an arterial blood sample was 
taken for determination of the hematocrit. The kidneys were 
ligated, excised and weighed. 
Urine analysis 
The urine volumes were measured gravimetrically. Urinary 
sodium and potassium concentrations (UNa' UK) were deter-
mined by flame photometry (FLM3 , Radiometer, Copenhagen, 
Denmark) and the osmolality of the urine samples was esti-
mated from the depression of the freezing point (Model 3MO, 
Advanced Instruments Inc., USA). 
Statistical analysis 
All data are presented as mean ± I SEM. The material was 
evaluated with analysis of variance (ANOV A). Within groups, 
values from the last control period were compared with the last 
expansion period. For comparisons between groups the last 
control periods and the last expansion periods were selected. A 
P value of less than 0.05 was considered to be statistically 
significant. The attenuating effect of haloperidol and SCH 23390 
on volume expansion-induced natriuresis (% Attenuation) was 
calculated as; 
% Attenuation = 
(
[V A(e) - V A(c» - [DA(e) - DA(C)]) 
* 100 [V A(e) - V A(c)] 
where VA(e) and VA(c) are the accumulated sodium excretions 
in vehicle-pretreated animals during expansion (e) and control 
(c) periods, respectively, and DA(e) and DA(c) are the corre-
sponding values in dopamine receptor antagonist-pretreated 
animals (haloperidol or SCH 23390). 
Results 
VE2, H-VE2 and S-VE2 
In vehicle-treated animals subjected to 2% VE, sodium 
excretion (UNa V) increased sixfold (Fig. 1), while the corre-
sponding values in haloperidol- and SCH 23390-treated animals 
were four- and fivefold, respectively. Haloperidol and SCH 
23390 attenuated the natriuretic response (accumulated sodium 
excretion) following 2% VE by 67% and 60%, respectively (Fig. 
4) . Mean arterial blood pressure (MAP, Table 1) was not 
different from the control value during the last expansion period 
irrespective of treatment. Urine osmolality (UOsm , Table 1) 
decreased by 36% in the vehicle-treated animals but remained 
statistically significantly unchanged in the haloperidol- and 
SCH 23390-treated groups. Free water clearance (CH,o, Table 
1) remained unchanged in vehicle treated animals -while it 
became more negative in haloperidol- and SCH 23390-treated 
animals. The hematocrit did not differ in the vehicle-, haloper-
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Fig. 1. Sodium excretion (U Nu V) before and during 2% isotonic vol-
ume expansion of body weight per hour in rats pretreated with vehicle 
(solid boxes), haloperidol (open circles) or SCH 23390 (open boxes). 
CI-C3 and EI-E3 refer to control periods 1-3 and expansion periods 1-3, 
respectively. kw: kidney weight. * P < 0.05 compared with correspond-
ing value of vehicle-treated group. 
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Fig. 2. Sodium excretion (UNaV) before and during 5% isotonic vo/-
ume expansion of body weight per hour in rats pretreated with vehicle 
(solid boxes). haloperidol (open circles) or SCH 23390 (open boxes). 
CI-C3 and EI-E3 refer to control periods 1-3 and expansion periods 1-3, 
respectively. kw: kidney weight. *P < 0.05 compared with correspond-
ing value of vehicle-treated group. 
idol and SCH 23390-treated animals at the end of the experi-
ment (42 ± 1%, 41 ± 1% and 42 ± 1%, respectively) . 
VE5, H-VE5 and S-VE5 
UNa V increased 29-fold in the vehicle-treated animals sub-
jected to 5% VE, while the corresponding values for haloperidol 
and SCH 23390-treated ones were 17- and 18-fold, respectively 
(Fig. 2). Haloperidol and SCH 23390 attenuated the natriuretic 
response following 5% VE by 46% and 56%, respectively. MAP 
(Table 2) was not different from the control value during the last 
expansion period irrespective of treatment. UOom (Table 2) 
decreased by 71 % in the vehicle-treated animals but by only 
32% and 38% in the haloperidol- and SCH 23390-treated groups. 
Free water clearance tended towards a less negative value in 
vehicle treated animals, while it became more negative in 
haloperidol- and SCH 23390-treated animals. The hematocrit at 
the end of the experiment was lower in the vehicle-treated than 
in the haloperidol- and SCH 23390-treated animals (38 ± 1%, 40 
± 1% and 41 ± 1%, respectively). 
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Fig. 3. Sodium excretion (UNaV) bef ore and during 10% isotonic 
volume expansion of body weight per hour in rats pretreated with 
vehicle (solid boxes), haloperidol (open circles) or SCH 23390 (open 
boxes) . CI-C3 and EI-E3 refer to control periods 1-3 and expansion 
periods 1-3, respectively. kw: kidney weight. 
VElO, H-VElO and S-VEIO 
In the vehicle-treated animals subjected to 10% VE, UNa V 
increased 130-fold, while the corresponding value in the halo-
peridol- and SCH 2339O-treated animals increased 138- and 
196-fold, respectively (Fig. 3). Although the accumulated UNa V 
during expansion was 22% and 19% lower in the haloperidol-
and SCH 23390-treated animals than in those which received 
vehicle alone, these differences were not statistically signifi-
cant. MAP (Table 3) was not different from the control value 
during the last expansion period irrespective of treatment. 
UOsm (Table 3) decreased by 89% in the vehicle-treated ani-
mals, and by 71% and 81% in the animals treated with haloper-
idol and SCH 23390, respectively. Free water clearance became 
positive in vehicle-treated animals, became more negative in 
hal9peridol-treated animals, while it tended to become less 
negative in SCH 2339O-treated animals . The hematocrit at the 
end of the experiment did not differ in the vehicle-, haloperidol-
and SCH 23390-treated animals (36 ± 1%, 37 ± 1% and 37 ± 
1%, respectively). 
MAP was 9% lower in the haloperidol-treated than in the 
vehicle-treated animals during the control periods. In SCH 
2339O-treated animals MAP was not different from vehicle-
treated animals. 
Discussion 
This study has shown that the attenuating effect of the 
dopamine receptor blockers, haloperidol and SCH 23390, on 
natriuresis induced by isotonic volume expansion is dependent 
on the degree of hypervolemia. The attenuation was most 
pronounced in the lower, more physiological level of hyper vol, 
emia and less pronounced in higher hypervolemic levels. The 
results indicate that at varying levels of hypervolemia, different 
systems contribute differently in the natriuretic response, which 
may explain some of the discrepancies in previously drawn 
conclusions regarding effector mechanisms in volume expan-
sion-induced natriuresis . The dopamine system seems to be 
relatively more important in promoting natriuresis at the lower 
physiological ranges of hypervolemia, whereas at more massive 
degrees of hypervolemia other factors are predominant. The 
identity of the latter factors cannot be determined from the 
present results. It is clear that caution should be observed when 
comparing results between studies if the degree of hypervol-
emia differs. 
As to the natriuretic effect of dopamine, Lee [10] has sug-
gested that it serves as an intrarenal natriuretic hormone. 
Dopamine produced within the kidney constitutes the bulk of 
urinary dopamine [11 , 12]. The major production site is in the 
proximal tubular cells [13], although the distal tubular cells may 
also contribute [14] . Present in the latter cells is the enzyme 
responsible for conversion of filtered I-dopa to dopamine (aro-
matic I-amino acid decarboxylase). Receptors for dopamine 
have been found in the renal arteries, glomeruli, proximal 
tubules and cortical collecting ducts [15]. The dopamine recep-
tors are classified into the subtypes DA\ and DA2 • DA\ receptor 
activation may increase renal blood flow, and stimulation of 
DA, and DA2 receptors may also increase the glomerular 
filtration rate. DAJ agonists inhibit fluid and electrolyte trans-
port directly by occupying DA\ receptors [reviewed in 15] . 
Haloperidol is an un selective dopamine receptor antagonist 
which blocks both the DA\ and DA2 receptor. The relative 
contribution of these receptor subtypes in the results from the 
present study caqqot be determined. SCH 23390 is a more 
selective DAI-receptor antagonist, indicating that the natri-
uretic attenuation was primarily due to an effect over DA1-
receptors. 
In the proximal tubules, dopamine has been found to inhibit 
Na-H antiport in the brush border membrane [16] and Na-K-
ATPase in the basolateral membrane [17]. Dopamine has also 
been shown to antagonize angiotensin II-mediated aldosterone 
secretion [18] and to inhibit the release of antidiuretic hormone 
from the hypophysis [19]. It has also been suggested that the 
natriuretic effect of ANF requires an intact dopamine system 
(20-22]. Dopamine infused intrarenally increases the renal 
blood flow [23] and in some cases also the glomerular filtration 
rate [23 , 24]. It seems, however, that endogenous dopamine 
does not play an important role in the regulation of renal blood 
flow and the glomerular filtration rate [25-27]. 
Dopamine excretion increases during volume expansion [2 , 
8], and both dopamine receptor antagonists [8, 9, 25, 28] and 
dopamine synthesis inhibitors [7] attenuate the natriuretic re-
sponse to volume expansion. Furthermore, infusion of dopa-
mine [23] and dopamine receptor agonists [29] results in natri-
uresis. In the light of the above, it seems that intrarenal 
dopamine acts physiologically as a paracrine substance in the 
control of sodium excretion by an action mediated primarily by 
renal tubular dopamine receptors. 
It may be argued that the doses of haloperidol and SCH 23390 
given in the present study do not achieve total blockade of 
dopamine effects during massive degrees of volume expansion. 
However, from the results presented in Figure 4 it can be 
deduced that the amount of sodium "retained" during blockade 
(that is, open bars minus marked bars), increases almost 
linearily with the degree of expansion. This would be in favor of 
an increasing dopamine-dependent natriuresis with increasing 
degrees of expansion in absolute terms, while it on a relative 
basis still is a decrease since other systems gain larger impact. 
If the absolute amount of retained sodium would level off with 
higher degrees of expansion, or be equal, one could suspect an 
insufficient dopamine blockade. 
It may be argued that the attenuation of the natriuresis 
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Fig. 4. Accumulated sodium excretion 
( UNa V) in rats pretreated with vehicle (open 
bars), haloperidol (hatched bars) or SCH 
23390 (dotted bars) during 2, 5 and 10% 
volume expansion of body weight per hour. 
*P < 0.05 compared with vehicle-treated 
group. NS = not significantly different from 
vehicle-treated group. kw: kidney weight, bw: 
body weight. Numbers in graph denotes the 
percentage attenuation of the natriuretic 
response compared with vehicle-treated 
group. 
Table 1. Parameters of renal function and blood pressure in vehicle-pretreated (VE2, N = 8), haloperidol-pretreated (H-VE2, N =-8) and 
SCH 23390-treated (S-VE2, N = 5) animals subjected to 2% acute isotonic volume expansion of body weight per hour 
Period Cl C2 C3 El E2 E3 
V pi . mi,,-l . g-J kidney wt 
VE2 2.1 ± 0.3 2.2 ± 0.4 2.3 ± 0.4 3.4 ± 0.9 8.4 ± 2.7 12.3 ± 4.3a 
H-VE2 1.4 ± 0.3 1.5 ± 0.3 1.6 ± 0.3 1.9 ± 0.3 2.4 ± 0.4 4.6 ± 1.6a 
S-VE2 1.3 ± 0.2 1.5 ± 0.2 1.7 ± 0.3 2.7 ± 0.7 4.7 ± 1.6 6.1 ± 2.5" 
UNamM 
VE2 52 ± 11 48 ± 10 49 ± 10 49 ± 11 52 ± 19 64 ± 25 
H-VE2 49 ± 11 47 ± 10 49 ± II 48 ± 9 45 ± 8 54 ± 11 
S-VE2 28 ± 4 26 ± 3 23 ± 3 22 ± 2 26 ± 3 36 ± 9 
UOsm mOsm . kg- 1 H2O 
VE2 2038 ± 151 2062 ± 132 2062 ± 105 1935 ± 121 1418 ± 217 1310 ± 273" 
H-VE2 2096 ± 105 2264 ± 90 2395 ± 82 2471 ± 101 2480 ± 84 2123 ± 251 
S-VE2 2038 ± 164 2141 ± 171 2128 ± 150 2093 ± 138 1808 ± 263 1735 ± 327 
C
Fo 
pi . min- J 
V 2 -12.3 ± 2 -12.8 ± 2 -13.6 ± 3 -17.3 ± 3 -18.4 ± 3 -16.8 ± 3 
H-VE2 -9.0 ± 2 -10.2 ± 2 -11.0 ± 2 -13.3 ± 2 -17.2 ± 2 -18.9 ± 2" 
S-VE2 -7.8 ± 2 -9.8 ± 2 -12.0 ± 2 -16.0±4 -18.0 ± 4 -19.9 ± 3" 
MAP mm Hg 
VE2 129 ± 5 127 ± 4 127 ± 4 127 ± 3 126 ± 3 124 ± 3 
H-VE2 113 ± 4 112 ± 4 112 ± 4 114 ± 3 115 ± 4 114 ± 4 
S-VE2 125 ± 3 125 ± 4 124 ± 4 121 ± 4 121 ± 4 120 ± 3 
Abbreviations are: CI to C3 and EI to E3 refer to control periods I to 3 and expansion periods 1 to 3, respectively; V, urine flow rate; UNa' 
sodium concentration; UOsm' urine osmolality; CH20, free water clearance; MAP, mean arterial blood pressure. 
" P < 0.05 compared with C3 of same group 
following volume expansion in the groups treated with haloper-
idol is attributable to a lower basal perfusion pressure since 
arterial blood pressure is lower than in the vehicle-treated 
animals. However, in the animals treated with SCH 23390, the 
attenuation of natriuresis is comparable with that of haloperi-
dol-treated ones, although the arterial blood pressure is not 
different from that of vehicle-treated animals. This would favor 
a major effect over dopamine receptors instead of perfusion 
pressure. 
In contrary to vehicle-treated animals, free water clearance 
decreased in animals treated with the dopamine receptor antag-
onists during isotonic volume expansion. If these changes are 
accompanied by differential suppression of plasma vasopressin 
levels or occur via vasopressin-independent intrarenal mecha-
nisms cannot be determined from the results in the present 
study. 
It is concluded that at varying degrees of hypervolemia, 
different physiological systems contribute differently in the 
renal natriuretic response. The dopamine system seems to be 
relatively more important for promoting natriuresis at the lower 
(physiological) ranges of hypervolemia, whereas in the high 
range of hypervolemia other factors have greater impact. 
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Table 2. Parameters of renal function and blood pressure in vehicle-pretreated (VE5, N = 9), haloperidol-pretreated (H-VE5, N = 8) and 
SCH 23390-treated (S-VE5, N = 6) animals subjected to 5% acute isotonic volume expansion of body weight per hour 
Period Cl C2 C3 El E2 E3 
'I pi . min-I. g-l kidney wt 
VE5 1.7 :':: 0.2. 1.7 :':: 0.2 1.8 :':: 0.3 5.0 :':: 1.3 16.6:':: 4.3 30.0:':: 5.8a 
H-VE5 1.2 :':: 0.2 1.3 :':: 0.1 1.5 :':: 0.2 2.2:':: 0.3 4.9 :':: 1.1 14.2 :':: 3.~ 
S-VE5 1.0 :':: 0.2 1.1 :':: 0.1 1.6 :':: 0.3 3.7 :':: 1.9 12.0 :':: 8.3 15.9 :':: 5.7a 
UNamM 
VE5 56 :':: 12 54:':: 13 53 :':: 14 43 :':: 11 66 :':: 12 75 :':: 19 
H-VE5 31 :':: 5 29 :':: 5 30 :':: 4 37 :':: 3 60:':: 14 61 :':: 16 
S-VE5 44:':: 13 41 :':: 11 30 :':: 6 39 :':: 4 34 :':: 3 46 :':: 7a 
UOsm mOsm . kg- l H2O 
VE5 2100:':: 102 2085 :':: 108 2176 :':: 84 1891 :':: 220 955:':: 206 641 :':: 223a 
H-VE5 2084 :':: 180 2220 :':: 151 2308 :':: 132 2350 :':: 56 2048 :':: 213 1575 :':: 260a 
S-VE5 1805 j: 292 1811 :':: 269 1944 :':: 200 1991 :':: 247 1726 :':: 352 1214 :':: 295a 
CE':o pi . min-l 
V 5 -10.2 :':: 1 -9.8:':: 1 -11.1 :':: 1 -19.5:':: I -17.0:':: 6 -5.3:':: 7 
H-VE5 -7.8:':: 1 -8.8:':: 2 -10.5:':: 2 -15.4 ± 2 -23.8:':: 3 -21.2 :':: 4a 
S-VE5 -5.9:':: 2 -6.1 :':: 2 -9.2:':: 2 -14.4:'::3 -12.7:':: 7 -21.1 :':: 63 
MAP mm Hg 
VE5 124 :':: 2 124 :':: 3 122 :':: 3 124 :':: 3 122 :':: 3 120 :':: 3 
H-VE5 111:'::2 112 :':: 2 112 :':: 2 117 :':: 2 117 :':: 3 115 :':: 3 
S-VE5 126 :':: 2 126 :':: 2 126 :':: 2 125 :':: 2 125 :':: 2 173 :':: 2 
Abbreviations are: CI to C3 and EI'to E3 refer to control periods I to 3 and expansion periods I to 3, respectively; V, urine flow rate; UNa' 
sodium concentration; UOsm ' urine osmolality; CH20, free water clearance; MAP, mean arterial blood pressure. 
a P < 0.05 compared with C3 of same group 
Table 3. Parameters of renal function and blood pressure in vehicle-pretreated (VEIO, N = 8), haloperidol-pretreated (H-VEIO, N = 8) and 
SCH 23390-treated (S-VEIO, N = 6) animals subjected to 10% acute isotonic volume expansion of body weight per hour 
Period CI C2 C3 EI E2 E3 
'I pi . min-I. g-l kidney wt 
VEIO 1.6 :':: 0.2 1.6 :':: 0.2 1.8 :':: 0.2 9.4 :':: 2.1 49.8:':: 8.3 82.4 :':: 10.73 
H-VEIO 1.2 :':: 0.1 1.4 :':: 0.1 1.3 :':: 0.1 2.5 :':: 0.6 15.8 :':: 5.2 52.8 :':: 10.58 
S-VEIO 1.2 :':: 0.2 1.5 :':: 0.3 1.5 :':: 0.2 4.9 :':: 1.1 31.3 :':: 8.2 65.9 :':: 12.3a 
UNamM 
VEIO 52 :':: 8 43:':: 6 41 :':: 6 52:':: 9 67:':: 19 79 :':: 21 
H-VEIO 46:':: 9 41 :':: 7 40:':: 7 52:':: 12 146 :':: 33 137:':: 39 
S-VEIO 40:':: II 28 ± 5 25 ± 5 35 ± 5 94 ± 27 % ± 29 
UOsm mOsm . kg- l H2O 
VEIO 2297 ± 133 2352 ± 136 2333 :':: 145 1436 :':: 252 426:':: 126 261 :':: 22a 
H-VEIO 1992 :':: 160 2098:':: 140 2261 :':: 126 2284 :':: 135 1445 :':: 308 661 ± 268a 
S-VEIO 1884 :':: 166 1979 :':: 159 2045 :':: 163 1823 :':: 193 778 :':: 216 380 :':: 948 
C~o pi . min-l 
V 10 -9.2:':: 1 -10.7:':: 1 -11.3 :':: I -23.6:':: 3 +16.8:':: 7 + 12.8:':: 7a 
H-VEI0 -7.0:':: I -8.1 :':: I -8.8:':: 1 -15.9:':: 3 -32.4 :':: 4 -23.9 :':: loa 
S-VEIO -6.9:':: 1 -8.5:':: 2 -9.2:':: 2 -22.9:':: 3 -21.6 :':: 8 -2.9:':: 10 
MAP mm Hg 
VEIO 124 :':: 1 124 :':: 1 123 :':: 1 127:':: I 126:':: 1 122 :':: 1 
H-VEIO 115 :':: 2 114:':: 2 115 :':: 2 121 :':: 2 119 :':: 1 115 :':: 3 
S-VEIO 122 :':: 3 122 :':: 3 122 :':: 2 122 :':: 3 121 :':: 3 120 :':: 3 
Abbr~viations are: Cl to C3 and El to E3 refer to control periods I to 3 and expansion periods 1 to 3, respectively; 'I, urine flow rate; UNa' 
sodium concentration; UOsm ' urine osmolality; CH20, free water clearance; MAP, mean arterial blood pressure. 
a P < 0.05 compared with C3 of same group 
the Schering Corporation (Bloomfield, New Jersey, USA) for the 
generous supply of haloperidol and SCH 23390, respectively. 
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